ABVC Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ABVC Nasdaq 8731 https://abvcpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ABVC Biopharma Inc

ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation - Jun 21st, 2022 12:30 pm
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC - Jun 16th, 2022 12:30 pm
ABVC BioPharma Announces Termination of Two Contracts - Jun 10th, 2022 12:30 pm
ABVC: Enrollment in ABV-1505 Part 2 ADHD Clinical Study Continues; First Patient Begins Treatment - Jun 7th, 2022 5:10 pm
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study - Jun 1st, 2022 12:30 pm
ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners - May 25th, 2022 12:30 pm
Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines - May 23rd, 2022 11:30 am
ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results - May 16th, 2022 9:46 pm
WallachBeth Capital Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering - May 16th, 2022 7:25 pm
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding - May 13th, 2022 12:30 pm
WallachBeth Capital Announces Pricing of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering - May 12th, 2022 1:00 pm
ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering - May 12th, 2022 12:30 pm
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated - May 10th, 2022 12:30 pm
ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process - May 5th, 2022 12:30 pm
ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed - May 3rd, 2022 12:30 pm
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study - Apr 28th, 2022 12:30 pm
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting - Apr 26th, 2022 12:30 pm
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results - Mar 31st, 2022 8:18 pm
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference - Mar 23rd, 2022 1:25 pm
ABVC: Lead Products Move Closer To Potential Approval; Important Clinical Studies Advancing - Mar 8th, 2022 11:15 am